MENU
+Compare
BIB
ETF ticker: NASDAQ
AS OF
Jul 2, 04:52 PM (EDT)
Price
$47.89
Change
+$1.51 (+3.26%)
Net Assets
47.39M

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BIB with price predictions
Jul 01, 2025

BIB sees its Stochastic Oscillator recovers from oversold territory

On June 24, 2025, the Stochastic Oscillator for BIB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BIB moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BIB crossed bullishly above the 50-day moving average on June 04, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 216 cases where BIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BIB as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BIB turned negative on June 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BIB broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Guardant Health (NASDAQ:GH).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology ETF is 5.28B. The market cap for tickers in the group ranges from 17.56M to 208.98B. AZN holds the highest valuation in this group at 208.98B. The lowest valued company is QTTB at 17.56M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 4%. For the same ETF, the average monthly price growth was 8%, and the average quarterly price growth was -7%. PRME experienced the highest price growth at 27%, while ALT experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 29%. For the same stocks of the ETF, the average monthly volume growth was -9% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 79
Price Growth Rating: 57
SMR Rating: 89
Profit Risk Rating: 89
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com